Please login to the form below

Not currently logged in
Email:
Password:

Janssen sways NICE with Stelara discount

UK health watchdog set to recommend drug in psoriatic arthritis after agreeing patient access scheme
NICE Stelara Janssen

The National Institute for Health and Care Excellence (NICE) is set to backtrack on negative guidance for a drug for psoriatic arthritis after agreeing a discount with its manufacturer.

NICE, which provides healthcare guidance for the NHS in England and Wales, issued a recommendation in May this year against extending the use of Janssen's Stelara (ustekinumab) to cover active psoriatic arthritis, a serious, progressive condition that can lead to progressive erosion of the joints.

However, the health watchdog has now issued new draft guidance that recommends the drug in this indication in “certain circumstances”, although only if Janssen provides the drug at a discount through a patient access scheme.

The circumstances required by NICE include if a person with psoriatic arthritis is unable to use one of several drugs already recommended for NHS reimbursement, or if a person has been treated with one or more of these drugs.

The medicines referenced by NICE are Janssen's own Simponi (golimumab) and Remicade (infliximab), AbbVie's Humira (adalimumab) and Pfizer's Enbrel (etanercept).

The draft guidance states that if a patient fits into the criteria outline by NICE, and Stelara is provided at the agreed discount through the patient access scheme, then the NHS should fund treatment with the drug.

Final guidance is still pending, however, and until then NHS bodies should make decisions locally on the funding of Stelara.

Peter Barnes, medical director at Janssen's UK subsidiary, said he was “pleased” with the new guidance.

“NICE's decision supports Janssen's view that ustekinumab offers value to the NHS as well as being clinically valuable. We are delighted that patients living with this condition may have access to another treatment option.”

Stelara is already recommended by NICE to treat the skin disease plaque psoriasis.

Article by
Thomas Meek

9th December 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics